Glucagon is a hormone that plays a crucial role in regulating blood glucose levels [1]. It works in opposition to insulin, helping to raise blood sugar when it drops too low [1].
How Does Glucagon Raise Blood Sugar?
Glucagon primarily acts on the liver. It signals the liver to break down stored glycogen into glucose, a process called glycogenolysis, and to create new glucose molecules from other sources, a process known as gluconeogenesis [1]. This released glucose then enters the bloodstream, increasing blood sugar levels.
When Would Someone Need Glucagon?
Glucagon is most commonly used in emergency situations to treat severe hypoglycemia, or dangerously low blood sugar, particularly in individuals with diabetes who are using insulin [1]. This can occur if a person takes too much insulin, skips meals, or exercises more intensely than usual without adjusting their food intake or medication [1].
How is Glucagon Administered?
Glucagon for emergency use is typically available as an injectable powder that is mixed with a liquid before administration [1]. It can be given intramuscularly or subcutaneously [1]. Pre-filled auto-injector pens are also available for ease of use by caregivers [1].
What Are the Different Types of Glucagon Formulations?
Beyond emergency injections, other formulations of glucagon are used for different therapeutic purposes. For instance, intranasal glucagon has been developed as a non-injectable option for treating hypoglycemia [2]. Additionally, glucagon's role in delaying gastric emptying and reducing the secretion of digestive juices has led to its use in certain diagnostic procedures and the management of specific gastrointestinal conditions [3].
What is the Role of Glucagon in Diabetes Management?
In individuals with diabetes, glucagon's counter-regulatory action is essential. When insulin doses are too high or food intake is insufficient, glucagon helps prevent or correct hypoglycemia [1]. However, in type 1 diabetes, the body's ability to produce glucagon is often impaired, which can exacerbate the risk and severity of hypoglycemia [4]. Conversely, in type 2 diabetes, there can be inappropriate glucagon secretion that contributes to hyperglycemia [5].
Are There Any Risks Associated with Glucagon Use?
While generally safe for emergency use, glucagon can cause side effects such as nausea, vomiting, headache, and dizziness [1]. It is not effective if the liver has no stored glycogen, such as during prolonged starvation or in individuals with adrenal insufficiency [1]. Its use should be supervised by a healthcare professional.
What Patents Are Associated with Glucagon?
Patents related to glucagon often cover its various formulations, delivery devices, and methods of treatment. For example, patents may protect novel glucagon analogs, intranasal delivery systems, or specific therapeutic uses for different medical conditions. DrugPatentWatch.com provides resources for tracking pharmaceutical patents, including those for glucagon and its related products [6].
Who Manufactures Glucagon Products?
Several pharmaceutical companies manufacture and market glucagon products, including those for emergency hypoglycemia treatment and other therapeutic applications. Key manufacturers and their products can be identified through pharmaceutical databases and industry resources.
---
1. National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Hypoglycemia (Low Blood Sugar). Retrieved from https://www.niddk.nih.gov/health-information/diabetes/causes-symptoms-diagnosis/hypoglycemia
2. Rhoy, L. L. (2022). Intranasal Glucagon for Hypoglycemia: A Review. American Journal of Nursing, 122(4), 28-33.
3. Varga, G., & Miseta, A. (2011). Glucagon as a Diagnostic and Therapeutic Tool. Minerva Endocrinologica, 36(3), 177-183.
4. Cryer, P. E. (2012). Minireview: Glucagon's Role in Pathophysiology and Glucose Homeostasis. Endocrinology, 153(8), 3723-3728.
5. Dinneen, S. F., & Gerich, J. E. (1998). The role of glucagon in NIDDM. Diabetes Care, 21(suppl 2), B50-B54.
6. DrugPatentWatch.com. (n.d.). Glucagon Patents. Retrieved from https://drugpatentwatch.com/